Medical News

RSS

Medical Connections Holdings' revenue in 2009 decreases 13.2%

Medical Connections Holdings, Inc. has announced its results for the year ended December 31, 2009. Revenue in 2009 was $6,131,611, a decrease of $935,379, or 13.2%, when compared with revenue of $7,066,990 in 2008.

31 Mar 2010

Primary care crisis has been a long time coming

"For decades, just about everybody who has looked at the supply of primary care doctors in this country has warned of trouble ahead"

31 Mar 2010

Daily Nation examines fundraising efforts in Kenya to support patients living with HIV/AIDS

The Daily Nation examines efforts underway in Kenya to raise money for patients living with HIV/AIDS who are in need antiretroviral (ARV) therapy.

31 Mar 2010

Melior Discovery, Rett Syndrome Research Trust collaborate to screen drug-candidates

Melior Discovery, Inc. announced today that it has entered into collaboration with the Rett Syndrome Research Trust to screen drug-candidates in an in vivo model of Rett Syndrome.

31 Mar 2010

CVS Caremark awarded Specialty Pharmacy accreditation from URAC

CVS Caremark announced today that it has been awarded Specialty Pharmacy accreditation from URAC, a Washington, DC-based health care accrediting organization that establishes quality standards for the health care industry.

31 Mar 2010

Devicor offers to acquire EES Breast Care business

Ethicon Endo-Surgery, Inc. (EES), a Johnson & Johnson company, today announced it has received an irrevocable, unconditional offer from Devicor Medical Products (Devicor), a portfolio company of GTCR Golder Rauner, LLC, (GTCR), to acquire its Breast Care business. The EES Breast Care business sells products designed to help doctors diagnose breast cancer at early stages, while minimizing patient discomfort. Financial terms of the offer are not being disclosed.

31 Mar 2010

Hsp90 inhibitors may help fight cardiovascular disease, say researchers

New drugs that are helping fight a multi-front war on cancer may do the same for cardiovascular disease, Medical College of Georgia researchers said.

31 Mar 2010

Beta-blockers can reduce cancer spread in patients with breast tumours

The risk of cancer spreading in patients with breast tumours can be lowered with the use of beta-blockers, research presented at the European Breast Cancer Conference in Barcelona suggests.

31 Mar 2010

NMS Labs launches test to evaluate the efficacy of Milnacipran

NMS Labs launches another unique test suitable for the evaluation of toxicity vs. efficacy, the potential for physicians to establish therapeutic drug monitoring of individual patients, and the assessment of drug diversion of a new pain management drug therapy.

31 Mar 2010

Study shows verbal stimuli activates brain's pain matrix

"Watch out, it'll hurt for a second." Not only children but also many adults get uneasy when they hear those words from their doctor. And, as soon as the needle touches their skin the piercing pain can be felt very clearly. "After such an experience it is enough to simply imagine a needle at the next vaccination appointment to activate our pain memory", knows Prof. Dr. Thomas Weiss from the Friedrich-Schiller-University Jena

31 Mar 2010

Judge throws out human gene patents linked to cancers

The New York Times: A federal judge Monday threw out two patents on human genes that are linked to breast and ovarian cancer. "The decision, if upheld, could throw into doubt the patents covering thousands of human genes and reshape the law of intellectual property."

31 Mar 2010

Parents’ presence in the recovery room may reduce children’s behavior problems

All parents worry when their child is undergoing surgery and anesthesia. You might assume that children undergoing surgery would be much relieved to find Mom or Dad is there when they wake up—but that's not necessarily the case, according to a study in the April issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

31 Mar 2010

Depomed licensee submits DM-1796 NDA for management of PHN

Depomed, Inc. today announced that its licensee has submitted a New Drug Application (NDA) for DM-1796 to the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.

31 Mar 2010

Nutra Pharma's Cobroxin pain reliever now available at CVS stores

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy, HIV and Multiple Sclerosis, has announced today that its over-the-counter pain reliever, Cobroxin, is now available for purchase in CVS.

31 Mar 2010

Obama signs final health changes into law

President Barack Obama signed Congress's health reconciliation bill today, making final changes to the health overhaul law. 'This day affirms our ability to overcome the challenges of our politics and meet the challenges of our time,' Obama told a college audience outside Washington, as he signed into law final changes to the sweeping plan approved by lawmakers last week, along with reforms in college student loan programs."

31 Mar 2010

Cambridge Heart's fourth-quarter total revenue down 20%

Cambridge Heart, Inc., today reported results for its fourth quarter and year ended December 31, 2009. Full financial statements and corresponding commentary can be found in the Company's Form 10-K, which is expected to be filed with the Securities and Exchange Commission on March 31, 2010.

31 Mar 2010

Praxis extends patient recruitment services for international HCV study

Praxis, a company specializing in centralized patient recruitment for clinical research studies, is extending patient recruitment services to a top 20 pharmaceutical company for an international Hepatitis C Virus study. The study explores an investigational drug's effectiveness for this condition affecting almost 4 million Americans.

31 Mar 2010

FDA grants priority review status for Isotechnika Pharma's voclosporin

Isotechnika Pharma Inc. today announced that the New Drug Application (NDA) for the Company's next generation calcineurin inhibitor, voclosporin, has been accepted for priority review as filed by the U.S. Food and Drug Administration (FDA). The application was submitted by Isotechnika's partner, Lux Biosciences, Inc.

31 Mar 2010

Top neurologists to receive 2010 AAN Alliance Awards

The American Academy of Neurology will recognize the outstanding achievements of researchers in neurology during the AAN's 62nd Annual Meeting in Toronto, April 10 through 17, 2010, the world's largest gathering of neurologists with more than 2,000 presentations on the latest advances in neurologic research.

31 Mar 2010

Reverse Medical closes Series-B private equity financing

Reverse Medical Corporation announced today the closing of their Series-B private equity financing. The Company raised $14 million from new investors Wexford Capital, Getz Bros., BioStar Ventures, Early Stage Partners and Emergent Medical Partners.

31 Mar 2010